A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04671667

Study #:
STUDY00147720

Start Date:
Feb 03, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04671667

View Complete Trial Details & Eligibility at ClinicalTrials.gov